LncRNA FOXCUT Stimulates the Progression of Endometrial Cancer

Crit Rev Eukaryot Gene Expr. 2021;31(5):59-66. doi: 10.1615/CritRevEukaryotGeneExpr.2021038472.

Abstract

Endometrial cancer (EC) is a common gynecological tumor and the third leading cause of cancer-related death in women. Previous research has proved that long noncoding RNA (lncRNA) FOXCUT acts as an oncogene in several cancers. This study ascertained that lncRNA FOXCUT was highly expressed in endometrial cancer cells. Overexpression of lncRNA FOXCUT promoted EC cell proliferation, invasion, and migration, as well as epithelial-mesenchymal transition (EMT). In addition, overexpression of lncRNA FOXCUT could inhibit the apoptosis of cancer cells and block EC cells in S phase, whereas silencing lncRNA FOXCUT had the opposite effect. Thus, lncRNA FOXCUT had a regulatory effect on promoting the progression of EC cells, which might provide novel potential targets for research on targeted therapy of EC.

MeSH terms

  • Apoptosis*
  • Cell Line, Tumor
  • Cell Movement*
  • Cell Proliferation*
  • Endometrial Neoplasms / genetics*
  • Endometrial Neoplasms / metabolism*
  • Epithelial-Mesenchymal Transition
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Oncogenes
  • RNA, Long Noncoding / genetics
  • RNA, Long Noncoding / metabolism*

Substances

  • RNA, Long Noncoding
  • long non-coding RNA FOXCUT, human